复方益肝灵胶囊预防抗结核药物性肝损伤的血清学指标Meta分析

Meta-analysis of Fufang Yiganling Capsules against Serum Makers of Anti-tuberculosis Drug-induced Liver Injury

目的:通过Meta分析方法,系统评价复方益肝灵胶囊在预防抗结核药物肝损伤方面的临床疗效。方法:通过检索国家知识基础设施数据库(CNKI)、中国学术期刊数据库(CSPD)、中文科技期刊数据库(CCD)、中国生物医学文献数据库(CBMdisc)及PubMed数据库,收集复方益肝灵胶囊在预防抗结核药物肝损伤方面的临床随机对照试验数据,通过RevMan 5.3软件进行Meta分析。结果:共纳入文献9篇,累计患者1674例。Meta分析结果显示,复方益肝灵胶囊可显著降低谷草转氨酶(MD=-14.78,95%CI为-21.36~-8.21,P<0.0001)、谷丙转氨酶(MD=-4.31,95%CI为-7.09~-1.52,P=0.002)、总胆红素(MD=-1.31,95%CI为-3.44~0.83,P=0.001)水平,可显著降低肝损伤率(MD=0.37,95%CI为0.30~0.45,P<0.00001)。结论:复方益肝灵胶囊预防抗结核药物肝损伤疗效确切。

Objective:We systematically evaluated the clinical efficacy of Fufang Yiganling Capsules in the prevention of anti-tuberculosis drug-induced liver injury by Meta-analysis system.Methods:Randomized controlled trials of oral Fufang Yiganling Capsules in the prevention of anti-tuberculosis drug-induced liver injury were collected by searching China National Knowledge Infrastructure(CNKI),China Science Periodical Database(CSPD),Chinese Citation Database(CCD),China Biology Medicine disc(CBMdisc)and PubMed databases.Meta-analysis was performed by RevMan 5.3 software.Results:A total of 9 pieces of literature were included,with a total of 1674 patients.Meta-analysis showed that Fufang Yiganling Capsules was able to decrease the levels of Aspartate aminotransferase[MD=-14.78,95%CI(-21.36 to-8.21),P<0.0001],Alanine aminotransferase[MD=-4.31,95%CI(-7.09 to-1.52),P=0.002]and Total bilirubin[MD=-1.31,95%CI(-3.44 to 0.83),P=0.001]significantly,thereby reducing the rate of liver injury[MD=0.37,95%CI(0.30 to 0.45),P<0.00001]significantly.Conclusion:Fufang Yiganling Capsules in the prevention of anti-tuberculosis drug-induced liver injury had definite curative effects.